Loading organizations...
§ Private Profile · San Francisco, CA, USA
Biomedical AI data provider building curated datasets and evaluation benchmarks for health organizations, offering 2M+ oncology AI datasets.
Aluna has raised $15.0M across 1 funding round.
Key people at Aluna.
Aluna was founded in 2024 by David Chu (Founder).
Aluna has raised $15.0M in total across 1 funding round.
Based in San Francisco, California, Aluna is a specialized business-to-business data provider that builds curated datasets and evaluation benchmarks specifically designed for biomedical artificial intelligence applications. The company primarily focuses on standardized oncology AI datasets, offering comprehensive multi-modal data architectures that currently include more than 2 million whole slide images distributed across over 25 distinct tumor types. These specialized datasets combine whole genome sequencing with paired clinical information and digitized pathology slides to directly assist health organizations and life science companies in developing advanced cancer diagnostic and treatment models. Operating with a core team of three full-time employees, the growing enterprise secured early institutional backing and participated in the prominent Y Combinator accelerator program as part of its Summer 2024 startup cohort. Aluna was officially founded in early 2024 by chief executive officer David Chu.
Key people at Aluna.
Aluna has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series B in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2023 | $15M Series B | Antonio Rodriguez | Matrix, Openview Venture Partners, SOSV, Warner Carr, MD, RHO Ventures | Announced |
Aluna is a biomedical AI company focused on respiratory health management, providing an AI-enabled platform that combines a portable, FDA-cleared spirometer with a mobile app to monitor lung function and manage chronic respiratory diseases such as asthma, COPD, and cystic fibrosis. The platform serves patients, caregivers, and healthcare providers by enabling daily lung health monitoring, symptom tracking, medication adherence, and environmental factor logging, with proprietary machine learning algorithms that help clinicians identify respiratory issues early and intervene to prevent exacerbations. Aluna’s solution addresses the problem of infrequent and reactive respiratory care by enabling continuous, remote patient monitoring, improving clinical outcomes and reducing costly hospital visits. The company has demonstrated strong growth momentum, recently closing a $15.3 million Series B funding round to expand its product reach and enhance its offerings[2][4].
Founded in 2013 in the San Francisco Bay Area by three asthmatics who met at the University of California, Berkeley, Aluna’s origins are deeply rooted in personal experience with respiratory disease. The founders’ shared challenges with asthma inspired them to create a technology-driven solution that brings clarity and peace of mind to patients and clinicians managing chronic respiratory conditions. Early traction came from close collaboration with leading academic medical centers and physicians, ensuring the platform’s safety, efficacy, and integration into existing treatment plans. The company has been recognized by the National Science Foundation and has steadily grown its funding base, reflecting confidence in its mission and technology[2][3][4].
Aluna rides the growing trend of digital health and remote patient monitoring, particularly accelerated by the need for continuous chronic disease management outside traditional clinical settings. The timing is critical as healthcare systems increasingly adopt AI and connected devices to improve patient outcomes and reduce costs. Market forces such as rising prevalence of respiratory diseases, advances in AI, and regulatory support for remote monitoring create a favorable environment for Aluna’s growth. By enabling daily lung function monitoring and data-driven clinical decision-making, Aluna influences the broader ecosystem by demonstrating how AI-powered tools can transform chronic disease management and patient engagement[2][4].
Looking ahead, Aluna is positioned to expand its product line, increase spirometer production, and deepen its AI capabilities to revolutionize respiratory care further. Trends such as personalized medicine, integration of environmental data, and broader adoption of remote monitoring will shape its journey. As Aluna scales, its influence may extend beyond respiratory health into other biomedical AI applications, leveraging its data-driven approach to improve clinical outcomes. The company’s mission to empower patients and clinicians with actionable lung health data ties back to its founding vision of transforming respiratory disease management through technology and collaboration[4][2].
Aluna was founded in 2024 by David Chu (Founder).
Aluna has raised $15.0M in total across 1 funding round.
Aluna's investors include Antonio Rodriguez, Matrix, Openview Venture Partners, SOSV, Warner Carr, MD, Rho Ventures.
